Abstract：
The association between a family history of breast cancer (FHBC) in female first-degree relatives (FDRs) and cancer risk in men has not been evaluated. This study aimed to compare the risks of overall and site-specific cancers in men with and without FHBC. A population-based study was conducted with 3 329 106 men aged ≥40 years who underwent national cancer screening between 2013 and 2014. Men with and without FHBC in their female FDRs were age-matched in a 1:4 ratio. Men without FHBC were defined as those without a family history of any cancer type in their FDRs. Data from 69 124 men with FHBC and 276 496 men without FHBC were analyzed. The mean follow-up period was 4.7 ± 0.9 years. Men with an FHBC in any FDR (mother or sister) had a higher risk of pancreatic, thyroid, prostate and breast cancers than those without an FHBC (adjusted hazard ratios [aHRs] (95% confidence interval [CI]): 1.35 (1.07-1.70), 1.33 (1.12-1.56), 1.28 (1.13-1.44) and 3.03 (1.130-8.17), respectively). Although an FHBC in any one of the FDRs was not associated with overall cancer risk, FHBC in both mother and sibling was a significant risk factor for overall cancer (aHR: 1.69, 95% CI:1.11-2.57) and increased the risk of thyroid cancer by 3.41-fold (95% CI: 1.10-10.61). FHBC in the mother or sister was a significant risk factor for pancreatic, thyroid, prostate and breast cancers in men; therefore, men with FHBC may require more careful BRCA1/2 mutation-related cancer surveillance.
摘要：
女性一级亲属（FDRs）的乳腺癌家族史（FHBC）与男性癌症风险之间的关系尚未得到评估。这项研究旨在比较有和没有FHBC的男性整体和特定部位癌症的风险。一项基于人群的研究是对3329106名年龄≥40岁的男性进行的，他们在2013年至2014年期间接受了国家癌症筛查。在女性FDR中有和没有FHBC的男性以1：4的比例进行年龄匹配。没有FHBC的男性被定义为在其FDR中没有任何癌症类型的家族史的男性。分析了来自69124名FHBC男性和276496名无FHBC男性的数据。平均随访时间为4.7±0.9年。在任何FDR（母亲或姐妹）中都有FHBC的男性患胰腺的风险较高，甲状腺，前列腺癌和乳腺癌比那些没有FHBC（调整的风险比[aHRs]（95％置信区间[CI]）：1.35（1.07-1.70），1.33(1.12-1.56),1.28(1.13-1.44)和3.03(1.130-8.17)，分别)。尽管FHBC在任何一个FDR中都与总体癌症风险无关，母亲和兄弟姐妹的FHBC是总体癌症的重要危险因素（aHR：1.69，95％CI：1.11-2.57），并使甲状腺癌的风险增加3.41倍（95％CI：1.10-10.61）。母亲或姐妹的FHBC是胰腺的重要危险因素，甲状腺，男性的前列腺癌和乳腺癌；因此，FHBC患者可能需要更仔细的BRCA1/2突变相关癌症监测.
